Semi-allogeneic vaccine for T-cell lymphoma
2007
Semi-allogeneic vaccine for T-cell lymphoma
Sample size: 10
publication
10 minutes
Evidence: high
Author Information
Author(s): Yu Jin, Kindy Mark S, Gattoni-Celli Sebastiano
Primary Institution: Medical University of South Carolina
Hypothesis
Can semi-allogeneic cell hybrids protect against T-cell lymphoma in mice?
Conclusion
Semi-allogeneic tumor cell hybrids provide significant protection against tumor growth in mice compared to control groups.
Supporting Evidence
- Vaccinated mice showed significantly smaller tumors compared to mock-vaccinated mice.
- Three of five vaccinated mice had no tumor growth after being challenged.
- Microarray analysis indicated an up-regulation of genes associated with Th-1 immune response.
Takeaway
This study shows that a special type of vaccine made from hybrid cells can help mice fight off a type of cancer called T-cell lymphoma.
Methodology
Mice were vaccinated with semi-allogeneic cell hybrids and then challenged with tumor cells to assess tumor growth.
Limitations
The study was conducted in mice, and results may not directly translate to humans.
Participant Demographics
C57BL/6 male mice, 10 weeks old.
Statistical Information
P-Value
< 0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website